Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study

•We report the use of ponatinib in chronic myelogenous leukemia (CML) patients who failed at least two lines of tyrosine kinase inhibitors (TKI) in a real-life setting.•This observational study reports similar rates of survival and molecular responses.•A slight increase in the cardiovascular ponatin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Experimental hematology 2018-11, Vol.67, p.41-48
Hauptverfasser:	Heiblig, Maël, Rea, Delphine, Chrétien, Marie-Lorraine, Charbonnier, Aude, Rousselot, Philippe, Coiteux, Valérie, Escoffre-Barbe, Martine, Dubruille, Viviane, Huguet, Françoise, Cayssials, Emilie, Hermet, Eric, Guerci-Bresler, Agnès, Amé, Shanti, Sackmann-Sala, Lucila, Roy, Lydia, Sobh, Mohamad, Morisset, Stéphane, Etienne, Gabriel, Nicolini, Franck E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cancer Cardiovascular Diseases - chemically induced Compassionate Use Trials Drug Resistance, Neoplasm Female Genes, abl Humans Imidazoles - adverse effects Imidazoles - therapeutic use Intention to Treat Analysis Kaplan-Meier Estimate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology Life Sciences Male Middle Aged Patient Selection Pragmatic Clinical Trials as Topic Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyridazines - adverse effects Pyridazines - therapeutic use Salvage Therapy Survival Analysis Treatment Failure Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!